HOME
ABOUT
Management
Board of Directors
ADDICTION
Alcohol Addiction
Limitations of Current AUD Therapies
Our Proposed Solution
TECHNOLOGY
Overview
Phase 2b Clinical Trial Results
History of Ondansetron Use for AUD
Strengths and Competitive Advantages
Newsroom
Press Releases
Media
INVESTORS
Overview
Analyst Coverage
News / Events
Company Information
Financial Information
Stock Data
SEC Filings
Corporate Governance
CONTACT
HOME
ABOUT
Management
Board of Directors
ADDICTION
Alcohol Addiction
Limitations of Current AUD Therapies
Our Proposed Solution
TECHNOLOGY
Overview
Phase 2b Clinical Trial Results
History of Ondansetron Use for AUD
Strengths and Competitive Advantages
INVESTORS
Overview
Analyst Coverage
News / Events
Company Information
Financial Information
Stock Data
SEC Filings
Corporate Governance
CONTACT
Financial Results
Investor Relations
Investor Relations
Overview
Analyst Coverage
News / Events
Company Information
Financial Information
Balance Sheet
Income Statement
Cash Flow
Financial Results
Stock Data
SEC Filings
Corporate Governance
2020
FY 2020
Fiscal Year Ended Dec 31, 2020
PDF
HTML
10-K
Filing
ZIP
XLS
HTML
XBRL
Q3 2020
Quarter Ended Sep 30, 2020
PDF
HTML
10-Q
Filing
ZIP
XLS
HTML
XBRL
Q2 2020
Quarter Ended Jun 30, 2020
PDF
HTML
10-Q
Filing
ZIP
XLS
HTML
XBRL
Q1 2020
Quarter Ended Mar 31, 2020
PDF
HTML
10-Q
Filing
ZIP
XLS
HTML
XBRL
2019
FY 2019
Fiscal Year Ended Dec 31, 2019
PDF
HTML
10-K
Filing
ZIP
XLS
HTML
XBRL
Q3 2019
Quarter Ended Sep 30, 2019
PDF
HTML
10-Q
Filing
ZIP
XLS
HTML
XBRL
Q2 2019
Quarter Ended Jun 30, 2019
PDF
HTML
10-Q
Filing
ZIP
XLS
HTML
XBRL
Q1 2019
Quarter Ended Mar 31, 2019
PDF
HTML
10-Q
Filing
ZIP
XLS
HTML
XBRL
2018
FY 2018
Fiscal Year Ended Dec 31, 2018
PDF
HTML
10-K
Filing
ZIP
XLS
HTML
XBRL
Q3 2018
Quarter Ended Sep 30, 2018
PDF
HTML
10-Q
Filing
ZIP
XLS
HTML
XBRL
Q2 2018
Quarter Ended Jun 30, 2018
PDF
HTML
10-Q
Filing
ZIP
XLS
HTML
XBRL
